$2.50
+0.18 (+7.76%)
Open$2.30
Previous Close$2.32
Day High$2.58
Day Low$2.30
52W High$19.99
52W Low$14.70
Volume—
Avg Volume220.0K
Market Cap33.87M
P/E Ratio31.04
EPS$0.55
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+740.0% upside
Current
$2.50
$2.50
Target
$21.00
$21.00
$13.91
$21.00 avg
$28.26
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.03M | 5.08M | 4.69M |
| Net Income | 1.10M | 914.1K | 814.2K |
| Profit Margin | 21.9% | 18.0% | 17.4% |
| EBITDA | 1.45M | 1.42M | 1.49M |
| Free Cash Flow | 1.19M | 761.6K | 738.1K |
| Rev Growth | -9.3% | +7.5% | +3.9% |
| Debt/Equity | 1.05 | 1.23 | 1.18 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |